Recursion Pharmaceuticals 주식 (NASDAQ: RXRX)

에 대한 최신 뉴스 Recursion Pharmaceuticals (NASDAQ:RXRX) 주식

Recursion Pharmaceuticals

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 혁신 분야에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다. 이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&amp;P 500과 비교

Equities

News

Markets

ARKQ

BLDE

TDOC

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 팔란티어 테크놀로지스(NYSE:PLTR)에 주목할 만한 투자를 했다. 이는 인공 지능(AI) 부문이 탄력을 받으면서 이루어진 움직임이다.

캐시 우드의 아크 인베스트는 AI 열풍 속에서 516만 달러 가치의 팔란티어 주식 매수

Biotech

Offerings

After-Hours Center

Movers

NVDA

리커전 파마슈티컬스(NASDAQ:RXRX)의 주가는 회사가 보통주 공모 제안을 발표한 후 수요일 시간외 거래에서 하락했다. 사건의 전말 (What Happened): 수요일 시장이 마감된 후 리커전은 인수된 공모를 통해 2억 달러 상당의 보통주를 제공 및 판매할 계획이라고 밝혔다. 모든 주식은 리커전에서 제공된다.

리커전 파마슈티컬스: 2억 달러 상당 공모 제안 발표 후 주가 하락

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals Inc

Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) affirms FY2026 sales outlook from $1.52 billion-1.77 billion to $1.52 billion-1.77 billion.

Guidance

VTOL

Bristow Group Affirms FY2026 Sales Guidance from $1.52B-1.77B to $1.52B-1.77B

Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) affirms FY2025 sales outlook from $1.44 billion-1.61 billion to $1.44 billion-1.61 billion.

Bristow Group Affirms FY2025 Sales Guidance from $1.44B-1.61B to $1.44B-1.61B

WIIM

CYTK

Cytek Biosciences shares are trading higher following better-than-expected Q3 earnings.

Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) narrows FY2024 sales outlook from $1.35 billion-1.42 billion to $1.35 billion-1.41 billion.

Bristow Group Narrows FY2024 Sales Guidance from $1.35B-1.42B to $1.35B-1.41B

Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 33.33 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $14.71 million which met the analyst consensus estimate. This is a 10.84 percent increase over sales of $13.27 million the same period last year.

Earnings

Earnings Beats

Arteris Q3 Adj $(0.08) Beats $(0.12) Estimate, Sales $14.71M Inline

Safety Insurance Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFT#NASDAQ">SAFT</a>) reported quarterly earnings of $1.10 per share which missed the analyst consensus estimate of $1.40 by 21.43 percent. This is a 86.44 percent increase over earnings of $0.59 per share from the same period last year. The company reported $295.28 million in sales this quarter. This is a 28.74 percent increase over sales of $229.36 million the same period last year.

Earnings Misses

SAFT

Safety Insurance Group Q3 EPS $1.10 Misses $1.40 Estimate, Sales $295.28M Up From $229.36M YoY

Select Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTTR#NYSE">WTTR</a>) reported quarterly earnings of $0.15 per share which met the analyst consensus estimate. The company reported quarterly sales of $371.349 million which beat the analyst consensus estimate of $350.908 million by 5.83 percent. This is a 4.60 percent decrease over sales of $389.273 million the same period last year.

WTTR

Select Water Solutions Q3 2024 GAAP EPS $0.15, Inline, Sales $371.349M Beat $350.908M Estimate

Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) reported quarterly earnings of $0.21 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $135.392 million which missed the analyst consensus estimate of $157.606 million by 14.09 percent. This is a 14.43 percent decrease over sales of $158.217 million the same period last year.

Mayville Engineering Q3 2024 Adj. EPS $0.21, Inline, Sales $135.392M Miss $157.606M Estimate

LoanDepot shares are trading higher after the company reported better-than-expected Q3 financial results.

Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) raises FY2024 sales outlook from $515.00 million-535.00 million to $520.00 million-540.00 million.

Limbach Holdings Raises FY2024 Sales Guidance from $515.00M-535.00M to $520.00M-540.00M  VS Est. 519.25M

UFCS

United Fire Group shares are trading higher after the company reported better-than-expected Q3 financial results.

BBAI

BigBear.ai shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.54 by 9.26 percent. This is a 34.09 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $194.500 million which missed the analyst consensus estimate of $196.574 million by 1.06 percent. This is a 3.43 percent decrease over sales of $201.400 million the same period last year.

HLIO

Helios Technologies Q3 2024 Adj. EPS $0.59 Beats $0.54 Estimate, Sales $194.500M Miss $196.574M Estimate

2024 ANNUAL GUIDANCE(1)
NOG is reiterating capital expenditure and production guidance and adjusting certain line items. Production taxes are being adjusted to reflect current expectations for the remainder of the year. Natural gas realizations and oil differentials are being adjusted to reflect results experienced year-to-date. Per unit cash G&amp;A is being lowered as the Company has reduced certain external expenses and continues to benefit from increasing production volumes.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Prior Guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Revised Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Annual Production (Boe per day)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">120,000 - 124,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">120,000 - 124,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Annual Oil Production (Bbls per day)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73,000 - 76,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73,000 - 76,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Capital Expenditures ($ in millions)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$890 - $970</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$890 - $970</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Wells Turned-in-Line ("TIL")</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">93.0 - 98.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">93.0 - 98.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Wells Spud</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73.0 - 78.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73.0 - 78.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating Expenses and Differentials:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Production Expenses (per Boe)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$9.15 - $9.40</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$9.15 - $9.40</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Production Taxes (as a percentage of Oil &amp; Gas Sales)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">9.0% - 9.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">8.5% - 9.0%(2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average Differential to NYMEX WTI (per Bbl)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($4.00) - ($4.85)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($4.00) - ($4.50)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average Realization as a Percentage of NYMEX Henry Hub (per Mcf)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">87.5% - 92.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">90.0% - 95.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">DD&amp;A Rate (per Boe)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$16.50 - $17.50</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$16.50 - $17.50</td>
</tr>
</tbody>
</table>
</figure>

NOG Reiterates Capital Expenditure And Production Guidance

loanDepot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.04) by 150 percent. The company reported quarterly sales of $314.598 million which beat the analyst consensus estimate of $275.995 million by 13.99 percent. This is a 18.42 percent increase over sales of $265.661 million the same period last year.

loanDepot Q3 2024 Adj. EPS $0.02 Beats $(0.04) Estimate, Sales $314.598M Beat $275.995M Estimate

SWIM

Latham Group shares are trading lower after the company reported worse-than-expected Q3 financial results and narrowed its FY24 sales guidance.

Carlyle Secured Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBD#NASDAQ">CGBD</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.48 by 2.08 percent. This is a 5.77 percent decrease over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $55.97 million which missed the analyst consensus estimate of $57.54 million by 2.74 percent. This is a 7.50 percent decrease over sales of $60.50 million the same period last year.

CGBD

Carlyle Secured Lending Q3 Adj $0.49 Beats $0.48 Estimate, Sales $55.97M Miss $57.54M Estimate

GMED

Globus Medical Sees FY24 Revenue $2.49B-$2.50B Vs $2.481B Est.; Adj. Diluted EPS $2.90-$3.00 Vs $2.85 Est.

Limbach Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.

MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) affirms FY2024 Adj EPS guidance from $1.50-1.62 to $1.50-1.62 vs $1.49 analyst estimate..

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MasterBrand expects FY 2024 Net sales Y/Y increase of low single digits; Adj. EBITDA: $385M-$405M; Adj. Diluted EPS: $1.50-$1.62  VS Est. 1.49

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

Interest Rate Regimes And ARKG: Underperformance Explained

Why Recursion is getting love as an AI and drug discovery top pick

Recursion, Exscientia seek support for merger ahead of special meeting

Recursion announced that the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral small molecul...

Recursion Pharmaceuticals doses first patient in Phase 2 trial of REC-3964

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 5,540 calls trading, 2x expected, and implied vol increasing over 2 points to...

Recursion Pharmaceuticals call volume above normal and directionally bullish

20:11 EDT Cathie Wood's ARK Investment buys 331K shares of Recursion Pharmaceuticals (RXRX) today Published first on TheFly – the ultimate source f...

Cathie Wood's ARK Investment buys 331K shares of Recursion Pharmaceuticals today

20:11 EDT Cathie Wood's ARK Investment buys 729K shares of Recursion Pharmaceuticals (RXRX) today Published first on TheFly – the ultimate source f...

Cathie Wood's ARK Investment buys 729K shares of Recursion Pharmaceuticals today

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2024 Update

20:20 EST Cathie Wood's ARK Investment buys 106K shares of Recursion Pharmaceuticals (RXRX) today Published first on TheFly – the ultimate source f...

Cathie Wood's ARK Investment buys 106K shares of Recursion Pharmaceuticals today

AMGN

ARKB

ARKF

ARKW

ARKX

BEAM

BIIB

BLUE

BMYMP

DKNG

EDIT

EXAI

EXAS

GNOM

GOOG

GOOGL

HELX

IDNA

NTLA

PACB

SDGR

Legal

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders

How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

Health Care

General

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

Opinion

AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMAR, PANL, BALY, RXRX on Behalf of Shareholders

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, ARC, RXRX on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPTN, RVNC, K, RXRX on Behalf of Shareholders

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Comments

Recursion Pharmaceuticals

뉴스

에 대한 최신 뉴스 Recursion Pharmaceuticals (NASDAQ:RXRX) 주식

금요일, 11월 01, 2024

화요일, 7월 02, 2024

목요일, 6월 27, 2024

화요일, 5월 14, 2024

금요일, 5월 10, 2024

금요일, 4월 12, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌